Literature DB >> 33236222

Tumor-infiltrating B cell is associated with the control of progression of gastric cancer.

Zhonglin Ni1, Dong Xing2, Teming Zhang3, Ning Ding2, Dan Xiang2, Zhiguang Zhao4, Jinmiao Qu5, Changyuan Hu6, Xian Shen3, Xiangyang Xue7, Jie Zhou8.   

Abstract

This study aimed to further explore the clinicopathological correlation of B cell infiltration in gastric cancer (GC) and its impact on prognostic. By immunohistochemical method, CD20+ B cells, CD3+ T cells, CD66b+ tumor-associated neutrophils, CD163+ tumor-associated macrophages, and CD57+ natural killer cells were analyzed in consecutive sections of 584 GC tissues and 69 normal adjacent tissues. Kaplan-Meier and Cox regression analyses determined the relationship between clinical relevance or prognosis and B cell infiltration. The correlation between total B cell infiltration and various T cell subtype infiltration in GC tissues from 407 patients in the TCGA data was also analyzed. Kaplan-Meier and Cox regression analyses determined the effects of total B cell infiltration and various B cell subtype infiltration on the prognosis of patients with GC. The infiltration level of CD20+ B cells was positively correlated with that of T cells (risk ratio [RR] = 0.0930), especially CD4+ T cells and CD8+ T cells (P < 0.05). A high level of CD20+ B cell infiltration was significantly associated with low lymph node involvement and low TNM stage (P < 0.05). High levels of CD20+ B cell infiltration were significantly associated with improvements in overall survival and disease-free survival. Univariate Cox regression and multivariate Cox regression analysis showed that CD20+ B cell infiltration was an independent protective factor of prognosis. Higher levels of class-switched memory B cell and plasma cell also reflected better overall survival, and class-switched memory B cell and plasma cell were independent protective factors for prognosis. The findings indicate that B cell infiltration in GC, especially switched memory B cells and plasma cells, has a significant effect on tumor progression and prognosis.

Entities:  

Keywords:  B cell infiltration; Gastric cancer; Plasma cell; Progress; Survival

Mesh:

Substances:

Year:  2020        PMID: 33236222     DOI: 10.1007/s12026-020-09167-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  3 in total

1.  Cigarette smoking and stomach cancer.

Authors:  A Nomura; J S Grove; G N Stemmermann; R K Severson
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

2.  Proinflammatory follicular helper T cells promote immunoglobulin G secretion, suppress regulatory B cell development, and correlate with worse clinical outcomes in gastric cancer.

Authors:  Hong Zhang; Rongxi Yue; Pengfei Zhao; Xuetao Yu; Junguo Li; Guoqing Ma; Jiahong Tang; Lixin Zhang; Liying Feng; Lidong Sun; Zongchang Song; Chunliang Guo; Ning Wang
Journal:  Tumour Biol       Date:  2017-06

3.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

  3 in total
  9 in total

1.  Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.

Authors:  Yong Liu; Tao Wang; Ziqi Fang; Junjie Kong; Jun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-21       Impact factor: 4.553

2.  High HDAC5 expression correlates with a poor prognosis and the tumor immune microenvironment in gastric cancer.

Authors:  Li Yuan; Can Hu; Pengcheng Yu; Zhehan Bao; Yuhang Xia; Bo Zhang; Yi Wang
Journal:  Ann Transl Med       Date:  2022-09

3.  CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer.

Authors:  Li Yuan; Jingli Xu; Yunfu Shi; Zhiyuan Jin; Zhehan Bao; Pengcheng Yu; Yi Wang; Yuhang Xia; Jiangjiang Qin; Bo Zhang; Qinghua Yao
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

4.  T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.

Authors:  Maria Christina Svensson; Albin Lindén; Jakob Nygaard; David Borg; Charlotta Hedner; Björn Nodin; Karin Leandersson; Karin Jirström
Journal:  Oncoimmunology       Date:  2021-05-20       Impact factor: 8.110

Review 5.  Role of the tumor immune microenvironment in tumor immunotherapy.

Authors:  Changsheng Zhou; Qianqian Liu; Yi Xiang; Xin Gou; Wengang Li
Journal:  Oncol Lett       Date:  2021-12-20       Impact factor: 2.967

6.  Construction of an Immune-Related lncRNA Signature That Predicts Prognosis and Immune Microenvironment in Osteosarcoma Patients.

Authors:  Yi He; Haiting Zhou; Haoran Xu; Hongbo You; Hao Cheng
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

7.  Identification of pyroptosis-related subtypes, development of a prognostic model, and characterization of tumour microenvironment infiltration in gastric cancer.

Authors:  Feng Cao; Jingtao Hu; Hongtao Yuan; Pengwei Cao; Yunsheng Cheng; Yong Wang
Journal:  Front Genet       Date:  2022-07-18       Impact factor: 4.772

8.  H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling.

Authors:  Jianxin Li; Ting Han; Xin Wang; Yinchun Wang; Xuan Chen; Wangsheng Chen; Qingqiang Yang
Journal:  World J Surg Oncol       Date:  2022-09-14       Impact factor: 3.253

9.  Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.

Authors:  Yuhan Wei; Jianwei Zhang; Xueke Fan; Zhi Zheng; Xiaoyue Jiang; Dexi Chen; Yuting Lu; Yingrui Li; Miao Wang; Min Hu; Qi Du; Liuting Yang; Hongzhong Li; Yi Xiao; Yongfu Li; Jiangtao Jin; Deying Wang; Xiangliang Yuan; Qin Li
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.